CorMedix Inc.
CRMD Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$7.94
KIRA · Stoqly’s AI analyst, in plain words
- CorMedix Inc. had $312M of revenue in fiscal 2025, up 617.0% on the year before. Over five years, revenue changed +319.8% a year on average.
- Its operating margin was 48.2%, up 99.6 pts: of every 100 in sales, about 48 is left after running the business.
- CorMedix Inc. made $163M of net profit in fiscal 2025.
- Free cash flow was $173M in fiscal 2025, 55.4% of revenue.
Market cap
$734M
P/E
3.6x
Revenue
$312M
Net income
$163M
Free cash flow
$173M
Operating margin
48.2%
CorMedix Inc. in 30 seconds · fiscal 2025
Are sales growing?
+617.0%
Yes. Sales grew 617.0% last year.
Does it make a profit?
52.3%
Yes. It keeps 52.3% of every sale as profit.
Does profit turn into cash?
55.4%
Yes. 55.4% of sales ends up as free cash.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
3.6x
One share costs 3.6 times its yearly profit per share.
What CorMedix Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- CorMedix Inc.
- CIK
- 0001410098
CorMedix Inc. · CRMD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.2M | $0.1M | — | $43.5M | $312M |
| Revenue growth | −20.2% | −65.7% | — | — | 617.0% |
| Net interest income | — | — | — | $1.4M | — |
| Gross margin | 22.0% | 94.3% | — | 92.7% | 88.5% |
| Operating margin | −15,420.4% | −46,825.7% | — | −51.4% | 48.2% |
| Net income | −$28.2M | −$29.7M | −$46.3M | −$17.9M | $163M |
| Net margin | −14,777.5% | −45,415.4% | — | −41.2% | 52.3% |
| Diluted EPS | −$0.75 | −$0.74 | −$0.91 | −$0.30 | $2.04 |
| Cash | |||||
| Cash from operations | −$21.2M | −$24.4M | −$38.4M | −$50.6M | $175M |
| Capital expenditure | $1.4M | $0.2M | $0.3M | $0.1M | $2.3M |
| Free cash flow | −$22.6M | −$24.6M | −$38.7M | −$50.7M | $173M |
| FCF margin | −11,828.4% | −37,578.1% | — | −116.7% | 55.4% |
| Share count change | 31.9% | 6.9% | 26.4% | −99.9% | 36.3% |
| Debt and strength | |||||
| Cash and short-term investments | $65.5M | $58.8M | $76.0M | $51.7M | $149M |
| Shareholders' equity | $62.8M | $55.1M | $70.1M | $84.7M | $405M |
| Current ratio | 12.4x | 9.4x | 7.0x | 3.4x | 2.1x |
| Interest coverage | −1,851.4x | −1,155.6x | −1,427.3x | −621.0x | 54.0x |
| Returns and quality | |||||
| Return on equity | −52.7% | −50.4% | −74.0% | −23.2% | 66.6% |
| Return on tangible equity | −44.9% | −53.9% | −66.1% | −21.7% | — |
| Piotroski F-score | 4 | 2 | — | — | 5 |
| Altman Z'' | 2.1 | −3.9 | −5.2 | −3.5 | 3.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.6M
4 insiders
Of sales under plans
59%
$1.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CorMedix Inc. · CRMD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.94 a share, the company is worth $734M: 3.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001410098). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.